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This brief overview of the factors determining lung deposition of aerosols provides background
information required by health care providers when instructing patients to use their prescribed
inhalers. We discuss differences in the optimal inhalation manoeuvres for each type of aerosol
generator and the difficulties patients face. Provision of short, clear instructions with demon-
stration of critical steps and checking technique during later clinical visits are necessary
if these aerosolised medications are to be fully beneficial.
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particle in relation to the diameter of a spherical particle of unit
density (water) that falls at the same rate, and relates the particle
size distribution as a function of mass e important for therapeutic
effects e and the behaviour of particles in terms of deposition.1Introduction
This paper discusses technical and theoretical aspects
of the use of inhaler devices and provides clear, practical
but critically important instructions for their use by
patients. The intention is to clarify these aspects for health
professionals who prescribe for and instruct patients.
Excellent publications on the characteristics of aerosols,
delivery devices and factors determining release and
de-aggregation of aerosolised particles are available1,2;
a recent publication provides detailed recommendations
for specialists in the use of inhalers.3 As inhaler devices are
most commonly prescribed and supervised by non-specialist
physicians and other health professionals, including
nurse practitioners, however, there is still a need for more
practical information suitable for such prescribers.
Aerosol generating devices (inhaler devices)
An account of the different inhalers used in medicine can
be found in the excellent review of Labiris and Dolovich.4
The most commonly used inhaler devices can be classified
into two groups: pressurised, metered-dose inhalers
(pMDIs) and dry powder inhalers (DPIs).5
Pressurised, metered-dose inhalers
The pMDI remains the most popular device prescribed
for inhalation therapy.6 Current pMDIs contain hydro-
fluoroalkane (HFA) 134a and 227ca propellants, which
replaced the chlorofluorocarbons (CFCs) that were dis-
continued by international agreement under the Montreal
protocol.6 HFAs deliver an aerosol plume with a lower
impact force (25.5 mN vs. 95.4 mN with CFC) at a higher
temperature (8 C vs. 29 C with CFC) than CFC propel-
lants.7 These properties and the fact that most new HFA
pMDIs have a smaller delivery orifice result in a more slowly
delivered aerosol plume, which facilitates inhalation and
produces less mouth irritation (the cold freon effect of
CFC devices).8 HFA devices may now carry the drug in
solution rather than suspension e as was usual with CFC
pMDIs e thus obviating the need to shake the device before
use.2,3,6 The prescribers can find which type the patient is
using by checking the drug manufacturer’s information
leaflet. Doses from the new inhalers feel and taste
different, and therefore patients accustomed to the old
pMDI devices who switch to a new HFA-propellant inhaler
should be warned of the differences and also told that it is
more difficult to feel the drug entering the mouth.2Once the HFA in current pMDI devices has evaporated
the drug can be deposited along the entire respiratory
tract.9 The aerosol contains a broad range of particle sizes
(0.5e10 mm) characterised by a typical mass median aero-
dynamic diameterf between 1 and 2 mm, although propel-
lant residue may enlarge them somewhat. Despite the small
particle size, only 55e60% of the dose reaches the respi-
ratory tract because one third impacts on the oropharynx
even if the inhalation technique is flawless.10 This is still an
improvement over the old CFC pMDIs, as 50e80% or more
of the dose delivered by those devices failed to reach the
lung.10,11 Slower inhalation reduces oropharyngeal impac-
tion of drug,12,13 and deep breathing facilitates peripheral
deposition.
Breath holding further facilitates sedimentation and
diffusion by Brownian motion.14 Coordination between
inhalation and generation of the aerosol is also essential.14
Firing the device too early or too late may completely
undermine delivery. Early firing e by even 0.5 s before the
onset of inspiration e can reduce deposition of aerosol
in the lung by 34%, while waiting until after the first half
of inspiration to fire the device typically reduces lung
deposition by 41%.15
In short, for efficient delivery of pMDI-generated aerosols
to the respiratory tract, inhaling from functional residual
capacity13 (following a maximal expiration), patients should
breathe in slowly and steadily at a rate of no more than
1 l s1. So, practically speaking, inhalation should take at
least 5e10 s. Furthermore, the inhaler should be activated
just after the onset of inspiration. The breath should then be
held for a further 6e10 s.12,16 These steps are summarized in
Table 1.
Even when patients are given detailed instructions the
intricacy of these manoeuvres leaves plenty of room for
error (see Table 2).17e28 For example, studies estimate
that on average more than 30% of patients poorly coordi-
nate activation of the device with inspiration. Other critical
errors include breathing in too quickly, stopping inhalation
immediately after firing the pMDI, activating the device
more than once during a single breath and failing to hold
the breath. Field studies suggest that these errors, like poor
coordination, are extremely frequent even in patients who
have ostensibly received additional instruction.29 Clinical
benefit is diminished by such errors because they can
Table 1 Correct technique for using a pMDIa.
(1) Take the cap off the inhaler mouthpiece.
(2) Shake the inhaler. (Not necessary with some HFA pMDIs. The patient should check the package instructions.)
(3) Hold the inhaler upright.
(4) Breathe out all the way.
(5) Place the inhaler mouthpiece between your lips (and teeth); keep your tongue down and out of the way of the mouthpiece.
(6) Fire the inhaler just after starting a very slow and very deep breath in.
(7) Continue to breathe in very slowly until your lungs are full. (It should take you at least 5 s to fill your lungs.)
(8) Remove the inhaler from your mouth and hold your breath while counting to 10 or as long as possible.
(9) Breathe out slowly.
a Modified from Newman et al. (1981)14. pMDI: pressurised metered-dose inhaler; and HFA: hydrofluoroalkane.
Inhaler instructions 497significantly limit aerosol deposition in the respiratory
tract.27,30
In conclusion, proper use of a pMDI requires careful and
repeated instruction, as well as vigilance on the part of the
prescriber, who must detect both obvious and subtle errors
of technique that may reduce drug delivery.31,32
Practical implications for prescribing pMDIs
Timing: if the aerosol bolus is released too late in the
respiratory manoeuvre, or if inspiration ceases on release
of the aerosol, the drug will not penetrate deeply into the
airways.14,15
Speed of inhalation: slow inspiration of a large tidal
volume of air reduces inertial deposition in the oral cavity
and larynx and facilitates deposition in the lower airways by
gravity (sedimentation) and diffusion.14,15 Errors in timing
and speed of inhalation are both critical and frequent.
Breath holding: holding a breath enhances peripheral
deposition of the aerosol.12,14 Without breath holding some
small particles may be expelled again from the airways
before they have had time to settle in the airway walls.
Priming and cleaning: when a pMDI device is first used or
has not been used for a week or more should be primed.
To prime a pMDI device fire two or three doses away intoTable 2 Errors observed during the various steps of the pMDI in
Step where error occurs Patients de
Remove the cap 0,27 2,17 3,
Shake the inhaler 7,27 15,23,2
Hold inhaler upright 0,23 2,20,24
Breathe out 30,28 34,22
Place inhaler between lips 6,22 12,25 1
Fire inhaler while breathing in slowly 10,20,26 16
Continue to inhale 26,20 30,23
Breath holding (5e10 s) 24,21,22 34
Patients whose technique is adequate overall (%) 11,17 21,23
Weighted a
Patients whose technique is poor overall (%) 16,18 19,23
Weighted a
Poor coordination 33% of 395
a Numbers show percentages of subjects making errors at each ste
homogeneous in design, disallowing statistical analysis, but the compa
difficulty and highlights the most difficult parts of the manoeuvre. S
paper. pMDIs: pressurised metered-dose inhalers.the air. Manufacturers’ recommendations for the care of
HFA pMDI inhalers include regular cleansing of the device’s
plastic holder, preferably with a damp cloth, to prevent
occlusion of the canister’s nozzle. (Check the package
insert for manufacturer’s instructions.)
Dose counting: pMDI devices without a dose-counter
offer no practical way of knowing when the device is
nearly empty and should be changed. Only by keeping
a daily tally and counting back from the total doses avail-
able in the canister will the patient know when to renew
the inhaler prescription.
pMDI modifications and add-on devices
Breath-activated pMDI devices (such as the Autohaler and
Easi-Breathe) that are fired by a spring triggered by airflow
at the onset of inspiration are very useful for patients who
cannot time their inspiration properly. The amount of
aerosol these devices deliver to the airways is equivalent to
the dose that good coordinators can achieve with conven-
tional pMDIs.33,34 These devices do not obviate the other
possible errors described above, however. To address these
other problems, valved holding chambers (VHCs) and spacer
devices have been developed.35,36 VHCs eliminate problems
with coordination and also reduce the velocity and masshalation manoeuvrea.
monstrating errors (%) Range (%)
23 524 0e5
6 20,25 26,20 27,22 32,17 34,28 5724 7e57
6,22 1017 0e10
42,25 46,23 6624 30e66
617 6e16
,18 19,27 24,22 26,28 34,23 37,17 43,25 47,21 6824 10e68
34,27 39,21 41,22 42,25 5817 26e58
,20 37,23 44,27 53,24 56,17,25 7718 24e77
24,28 25,21 38,18 56,22 7019
verage (1317 patients)Z 34.3
25,17 28,28 30,19 3327
verage (5117 patients)Z 31.8
5 patients,27 43% of 746 patients,25 and 26% of 556 patients28
p of the manoeuvre in the cited studies. These studies were not
rison nevertheless provides a general impression of the amount of
uperscript numbers refer to references listed at the end of the
498 J. Sanchis et al.median aerodynamic diameter of the aerosol particles as
they enter the respiratory tract. The largest particles impact
inside the VHC and others evaporate into smaller ones,
resulting in increased delivery of aerosol to the peripheral
airways.35 Slow inspiration and a breath hold lasting six to
ten seconds are still required when using a VHC. As VHCs are
bulky, many patients require convincing before trusting in
the benefits of using them.37 Another disadvantage of VHCs
is that they may acquire a static charge that attracts aerosol
particles to the wall of the chamber; this effect is counter-
acted by periodically immersing the VHC in diluted
household detergent (1:5000) and then drip drying or air
drying, or by using a metal spacer instead.38,39 However,
spacer tubes, which simply allow extra evaporation of the
aerosol particles, thus reducing pharyngeal impaction, are
less useful than VHCs.Practical implications for prescribing add-on
devices for patients who use modified pMDIs
Where the patient has irremediably poor coordination, an
additional large-volume spacer or a breath-activated pMDI
can be prescribed. Some experts suggest that every patient
taking an inhaled corticosteroid should use a spacer in
order to benefit from the increased amount of drug deliv-
ered to the respiratory tract and the reduction in risk of
unwanted effects such as oral thrush. National and inter-
national asthma guidelines particularly recommend routine
use of a large-volume spacer by young children.40 In addi-
tion to prescribing a spacer for patients with oral thrush
and dysphonia, the physician may consider substituting
a DPI for the pMDI.41 Yet another alternative is to treat
with an inhaled corticosteroid that is not activated in the
mouth but only in the respiratory tract; an example is
ciclesonide.Dry powder inhalers
DPIs, which are breath-activated, are now widely used as
alternatives to pMDIs. Two types are on the market. One
delivers a single-dose generally housed in rigid gelatine
capsules (Rotahaler, Aerolizer, Spiriva-Handihaler), to
be placed in a holder (delivery chamber) inside the DPI.
The inhaler is usually activated when the capsule is piercedTable 3 Correct technique for using a DPIa.
(1) Remove mouthpiece cover.
(2) Sit upright or stand.
(3) Prime the inhaler according the manufacturer’s instructions.
(4) Exhale completely, away from the mouthpiece.
(5) Put the mouthpiece between your teeth and close your lips
(6) Inhale as rapidly and forcefully as possible, attempting to br
(7) Take the inhaler out of your mouth.
(8) Hold your breath for about 10 s or as long as you can.
(9) Breathe out slowly.
(10)Replace the cover.
a The steps are described in a similar way to those recommended b(once or twice) with needles fixed to pressure buttons.
Perforation allows the drugecarrier mix to be de-aggregated
and aerosolized by the turbulent flow generated when the
patient inhales. Some patients require two inhalations
to empty the capsule. The second type contains multiple
doses enclosed in a reservoir (Turbuhaler, Novolizer,
Easyhaler) or a foilefoil strip that is mechanically trans-
ported through the device (Diskus).
Each DPI requires a specific priming procedure, the
observance of which is critical in making the drug available
for inhalation. Therefore, a clear instruction to the user is
mandatory. (Check the manufacturer’s instruction leaflet
for specifics.) The basic steps in a correct inhalation
manoeuvre with a DPI are listed in Table 3. Not closing the
mouthpiece until a click is heard, not piercing the capsule,
or piercing it more than twice, and not releasing the
piercing buttons afterwards may also be critical errors
specific to certain single-dose DPIs. Not sliding the lever
back until a click is heard or sliding it after inhalation has
started are critical errors specific to the Diskus device.42
Not holding the inhaler upright when twisting the bottom
grip or not twisting it in both directions are critical errors
with the Turbuhaler. Factors that determine the aerosol
particle size and thus substantially affect particle deposi-
tion in the respiratory tract are the acceleration and
the velocity of the airflow during inspiration (optimally
>1 l s1).43 These factors in turn depend on the designs
of the particular devices, which offer different degrees
of airflow resistance.44 DPIs with a low internal resistance
(Spinhaler, Cyclohaler) require a high inspiratory flow
(1.5 l s1) whereas those with a higher resistance
(Twisthaler, Easyhaler and Turbuhaler) may require
a lower inspiratory flow to generate sufficient turbulence
for efficient particle aerosolisation (<1 l s1). Those in the
mid-range of resistance include the Accuhaler/Diskus,
Clickhaler and Novolizer.3
The In-Check Dial can be used to measure a patient’s
inspiratory flow rate across a range of resistances matched
to inhaler devices.45 This training tool enables clinicians
to demonstrate to patients that they can generate
a sufficient flow rate for their prescribed device, and
particularly to identify patients with a very low inspiratory
flow rate (such as young children and those with severe,
fixed airways obstruction) who may not be able to generate
sufficient flow and for whom the device may be
unsuitable.45e47 Another potential disadvantage of DPIs isaround it.
eathe in faster as you go.
y Laube et al. (2011)3. DPI: dry powder inhaler.
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Inhaler instructions 499that de-aggregation of the drugecarrier mix may be
affected by humidity or large temperature changes, which
may reduce deposition.48 Some patients may blow into the
device before inhalation, dispersing the drug powder or
clogging the tube, while others may forget to hold their
breath.
Contrary to popular belief, patients do not always find
DPIs easier to use or use them more efficiently. In a recent
study of 1664 adult patients (mean age 62 years), critical
errors were observed in 12% of patients using a pMDI, 35%
of patients using the Accuhaler/Diskus and 44% using the
Turbuhaler.49 Other studies, however, report comparable
frequencies of critical errors with both pMDI and DPI
devices (see Tables 2 and 4). Some potential errors are
common to all DPIs whereas others are specific to particular
devices (Table 4). More than 10% of patients fail to prime
their device.24,49 It is difficult to tell whether devices
like the Turbuhaler or the Accuhaler/Diskus have been
primed, although others, such as the Novolizer with its
coloured indicator, demonstrate this clearly.
Practical implications for prescribing DPIs
Training: if a DPI is to be used, it is essential for the
prescribing clinician, health care professional or pharma-
cist to instruct the patient in proper technique. Training
must be device-specific; placebo inhalers can be helpful.
Speed of inhalation: inhalation must be brisk and
with acceleration (essentially, for the purposes of patient
instruction, as hard and as fast as possible). Unless the
correct flow for a specific device is achieved, drug deposi-
tion in the lung will be reduced.43 The In-Check device
offers the means to verify flow objectively. As with pMDIs,
the patient should exhale fully before breathing in, with
the mouth away from the device.
Breath holding: breath should be held for 10 s after
inhalation if possible.
Priming and cleaning: as drug delivery may be affected
by failure to prime, device-specific priming instructions are
essential. (See manufacturer’s package insert.) Cleaning
should be done with a moist towelette, and the device
should be dried afterwards and protected from damp.
Dose counting: most multiple-dose DPIs now incorporate
a dose counter.
Storage: avoid storage of a DPI in a humid environment.
Education and instruction
Asthma education empowers patients to manage their
disease and increases their awareness of danger signs.57
Patients with a positive attitude towards controlling their
asthma are more likely to adhere to therapy.58 Regular
medical review provides an opportunity to raise patients’
expectations, helps them understand how to monitor their
asthma and increases awareness of possible factors (such
as poor inhaler technique) that may prevent them from
attaining control.57 Successful training in inhaler technique
depends upon effective communication of proper tech-
nique and its purpose, and monitoring to ensure that the
skills have been learned and retained.59 Of all the training
approaches possible, personal or small group demonstration
Table 5 Points to remember when planning inhaler instruction.
1. Patients with defective inhaler technique receive less drug and have less effect,30 suffer more symptoms and make more
emergency visits because poor asthma control.27,46
2. Patients who improve their technique ameliorate their symptoms of asthma or COPD.63
3. Verbal instruction is effective in teaching correct inhaler technique18 and requires less than 15 min.23
4. Technique deteriorates over time, so instruction should be repeated in follow-up visits.59,65 Repeated instruction improves
adherence to the therapeutic regime.61
5. When the various available inhalers are used correctly, there are no differences in clinical results.66,67
6. The quality of the initial instruction seems to be of paramount importance for the outcome of inhalation therapy.68
Components of an instruction session69,70 (have two sets of placebo inhalers ready).
1. Conduct the session personally or delegate it to a specifically trained helper.
2. Explain verbally the inhalation manoeuvre to the patient and the reasons for each of its steps.
3. Demonstrate practically the manoeuvre, describing each step.
4. Repeat the demonstration without an explanation.
5. Repeat it again with verbal comments.
6. Ask the patient to demonstrate the manoeuvre.
7. Explain any defects you observe in the patient’s performance.
8. Repeat your demonstration and then ask the patient to repeat the manoeuvre.
10. Arrange for follow-up instruction at further appointments.
Whenever possible and particularly to paediatric or elderly patients, provide instruction to patients’ relatives or care-givers.
500 J. Sanchis et al.has so far proven most effective.18,60 Other training
methods for inhaler use include written indications, illus-
trations, audio-visual demonstrations and interactive
computer programs.18,50 Periodic re-training is needed as
inhaler technique deteriorates with time.50,61 Special
provision should be made for the elderly, who may have
more trouble learning good inhaler technique and a greater
tendency to forget it, while small children may require
a particular teaching environment to hold their atten-
tion.22,62 Intuitively, therapeutic success will be more likely
if patients are prescribed a device that they have chosen,
are happy with and can use well. Although not always
practicable, use of a single type of device to deliver all
medications it is preferable since coping with a variety
of devices increases the likelihood of error.56 Some of the
most important facts about inhaler instruction are sum-
marised in Table 5.63e70
In summary, efficient use of both pMDIs and DPIs requires
more than a perfunctory inspection of technique.55 Subtle
errors are easily missed while some must be detected by
objective measurement. The health professional must be
determined to go the extra mile to check technique care-
fully and regularly since no drug is effective until delivered.Conflicts of interest
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